Cargando…
Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
The Janus Kinases (JAKs) are a family of intracellular tyrosine kinases that provide transmission signals from cytokine, interferons, and many hormones receptors to the nucleus resulting in synthesis of many biologically active compounds and changing cell metabolism and function. That was theoretica...
Autor principal: | Kotyla, Przemyslaw J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971265/ https://www.ncbi.nlm.nih.gov/pubmed/29862290 http://dx.doi.org/10.1155/2018/7492904 |
Ejemplares similares
-
Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
por: Kotyla, Przemysław J., et al.
Publicado: (2020) -
Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
por: Kotyla, Przemysław J., et al.
Publicado: (2021) -
Janus kinase inhibitors: jackpot or potluck?
por: Pavithran, Keechilat, et al.
Publicado: (2012) -
The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
por: Veale, Douglas J, et al.
Publicado: (2019) -
Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)